RNA, U4 small nuclear 78, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4-78P profile across patient tissues and cancer cell-line models. RNU4-78P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RNU4-78P is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, RNU4-78P RNA expression shows 16,491 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BLCA, STAD, and DLBC as cancer lineages where RNU4-78P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4-78P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4-78P survival associations across molecular data types. RNU4-78P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4-78P RNA expression–survival associations across cancer types. High RNU4-78P expression shows unfavorable associations in UCEC and STAD, but favorable associations in BLCA, HNSC, SKCM and LAML. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for RNU4-78P RNA expression.
This table summarizes RNU4-78P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4-78P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4-78P shows higher tumor expression in STAD, BLCA and LIHC. The STAD box plot shows higher RNU4-78P RNA expression in tumor versus normal tissue (log2 FC = +0.604, t-test p = .006).
This table shows molecular features associated with RNU4-78P in patient tissues and cancer cell lines. In patient samples, RNU4-78P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
